Thomas Koch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Thomas Koch has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Volker Höllt
Department of Pharmacology and Toxicology, Otto-von-Guericke University, Magdeburg, Germany
9 shared publicationsHelmut Schröder
Department of Pharmacology and Toxicology, Otto-von-Guericke University, Magdeburg, Germany
4 shared publications- Stefan Schulz
Institute of Organic Chemistry Technische Universität Braunschweig Braunschweig Germany
4 shared publications Lars‐Ove Brandenburg
Department of Pharmacology and Toxicology, Otto-von-Guericke University, Magdeburg, Germany
3 shared publicationsAndrea Beyer
2 shared publicationsDai-Fei Wu
Department of Pharmacology and Toxicology, Otto-von-Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany
2 shared publications
Latest Publications
- Open Access
- 21 July 2009
- Published by Wiley in Journal of Neurochemistry
- Vol. 110 (4) , 1288-1296
μ‐Opioid receptor‐stimulated synthesis of reactive oxygen species is mediated via phospholipase D2
We have recently shown that the activation of the rat μ‐opioid receptor (MOPr, also termed MOR1) by the μ‐agonist [d‐Ala2, Me Phe4, Glyol5]enkephalin (DAMGO) leads to an increase in phospholipase D2 (PLD2) activity and an induction of receptor endocytosis, whereas the agonist morphine which does not induce opioid receptor endocytosis fails to activate PLD2. We report here that MOPr‐mediated activation of PLD2 stimulates production of reactive oxygen molecules via NADH/NADPH oxidase. Oxidative stress was measured with the fluorescent probe dichlorodihydrofluorescein diacetate and the role of PLD2 was assessed by the PLD inhibitor d‐erythro‐sphingosine (sphinganine) and by PLD2‐small interfering RNA transfection. To determine whether NADH/NADPH oxidase contributes to opioid‐induced production of reactive oxygen species, μ‐agonist‐stimulated cells were pre‐treated with the flavoprotein inhibitor, diphenylene iodonium, or the specific NADPH oxidase inhibitor, apocynin. Our results demonstrate that receptor‐internalizing agonists (like DAMGO, β‐endorphin, methadone, piritramide, fentanyl, sufentanil, and etonitazene) strongly induce NADH/NADPH‐mediated ROS synthesis via PLD‐dependent signaling pathways, whereas agonists that do not induce MOPr endocytosis and PLD2 activation (like morphine, buprenorphine, hydromorphone, and oxycodone) failed to activate ROS synthesis in transfected human embryonic kidney 293 cells. These findings indicate that the agonist‐selective PLD2 activation plays a key role in the regulation of NADH/NADPH‐mediated ROS formation by opioids.
- 21 July 2009
- Published by Wiley in Journal of Neurochemistry
- Vol. 110 (4) , 1288-1296
Open Accessμ‐Opioid receptor‐stimulated synthesis of reactive oxygen species is mediated via phospholipase D2
We have recently shown that the activation of the rat μ‐opioid receptor (MOPr, also termed MOR1) by the μ‐agonist [d‐Ala2, Me Phe4, Glyol5]enkephalin (DAMGO) leads to an increase in phospholipase D2 (PLD2) activity and an induction of receptor endocytosis, whereas the agonist morphine which does not induce opioid receptor endocytosis fails to activate PLD2. We report here that MOPr‐mediated activation of PLD2 stimulates production of reactive oxygen molecules via NADH/NADPH oxidase. Oxidative stress was measured with the fluorescent probe dichlorodihydrofluorescein diacetate and the role of PLD2 was assessed by the PLD inhibitor d‐erythro‐sphingosine (sphinganine) and by PLD2‐small interfering RNA transfection. To determine whether NADH/NADPH oxidase contributes to opioid‐induced production of reactive oxygen species, μ‐agonist‐stimulated cells were pre‐treated with the flavoprotein inhibitor, diphenylene iodonium, or the specific NADPH oxidase inhibitor, apocynin. Our results demonstrate that receptor‐internalizing agonists (like DAMGO, β‐endorphin, methadone, piritramide, fentanyl, sufentanil, and etonitazene) strongly induce NADH/NADPH‐mediated ROS synthesis via PLD‐dependent signaling pathways, whereas agonists that do not induce MOPr endocytosis and PLD2 activation (like morphine, buprenorphine, hydromorphone, and oxycodone) failed to activate ROS synthesis in transfected human embryonic kidney 293 cells. These findings indicate that the agonist‐selective PLD2 activation plays a key role in the regulation of NADH/NADPH‐mediated ROS formation by opioids.
- 24 June 2008
- Published by Springer Nature in Cell Research
- Vol. 18 (7) , 768-779
Membrane glycoprotein M6A promotes μ-opioid receptor endocytosis and facilitates receptor sorting into the recycling pathway
The interaction of μ-opioid receptor (MOPr) with the neuronal membrane glycoprotein M6a is known to facilitate MOPr endocytosis in human embryonic kidney 293 (HEK293) cells. To further study the role of M6a in the post-endocytotic sorting of MOPr, we investigated the agonist-induced co-internalization of MOPr and M6a and protein targeting after internalization in HEK293 cells that co-expressed HA-tagged MOPr and Myc-tagged M6a. We found that M6a, MOPr, and Rab 11, a marker for recycling endosomes, co-localized in endocytotic vesicles, indicating that MOPr and M6a are primarily targeted to recycling endosomes after endocytosis. Furthermore, co-expression of M6a augmented the post-endocytotic sorting of δ-opioid receptors into the recycling pathway, indicating that M6a might have a more general role in opioid receptor post-endocytotic sorting. The enhanced post-endocytotic sorting of MOPr into the recycling pathway was accompanied by a decrease in agonist-induced receptor down-regulation of M6a in co-expressing cells. We tested the physiological relevance of these findings in primary cultures of cortical neurons and found that co-expression of M6a markedly increased the translocation of MOPrs from the plasma membrane to intracellular vesicles at steady state and significantly enhanced both constitutive and agonist-induced receptor endocytosis. In conclusion, our results strongly indicate that M6a modulates MOPr endocytosis and post-endocytotic sorting and has an important role in receptor regulation.
- 24 June 2008
- Published by Springer Nature in Cell Research
- Vol. 18 (7) , 768-779
Membrane glycoprotein M6A promotes μ-opioid receptor endocytosis and facilitates receptor sorting into the recycling pathway
The interaction of μ-opioid receptor (MOPr) with the neuronal membrane glycoprotein M6a is known to facilitate MOPr endocytosis in human embryonic kidney 293 (HEK293) cells. To further study the role of M6a in the post-endocytotic sorting of MOPr, we investigated the agonist-induced co-internalization of MOPr and M6a and protein targeting after internalization in HEK293 cells that co-expressed HA-tagged MOPr and Myc-tagged M6a. We found that M6a, MOPr, and Rab 11, a marker for recycling endosomes, co-localized in endocytotic vesicles, indicating that MOPr and M6a are primarily targeted to recycling endosomes after endocytosis. Furthermore, co-expression of M6a augmented the post-endocytotic sorting of δ-opioid receptors into the recycling pathway, indicating that M6a might have a more general role in opioid receptor post-endocytotic sorting. The enhanced post-endocytotic sorting of MOPr into the recycling pathway was accompanied by a decrease in agonist-induced receptor down-regulation of M6a in co-expressing cells. We tested the physiological relevance of these findings in primary cultures of cortical neurons and found that co-expression of M6a markedly increased the translocation of MOPrs from the plasma membrane to intracellular vesicles at steady state and significantly enhanced both constitutive and agonist-induced receptor endocytosis. In conclusion, our results strongly indicate that M6a modulates MOPr endocytosis and post-endocytotic sorting and has an important role in receptor regulation.
- 1 February 2008
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 117 (2) , 199-206
Role of receptor internalization in opioid tolerance and dependence
- 1 February 2008
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 117 (2) , 199-206
Role of receptor internalization in opioid tolerance and dependence
- Open Access
- 1 July 2007
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 282 (30) , 22239-22247
Membrane Glycoprotein M6a Interacts with the μ-Opioid Receptor and Facilitates Receptor Endocytosis and Recycling
- 1 July 2007
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 282 (30) , 22239-22247
Open AccessMembrane Glycoprotein M6a Interacts with the μ-Opioid Receptor and Facilitates Receptor Endocytosis and Recycling
- Open Access
- 15 March 2006
- Published by Wiley in Journal of Neurochemistry
- Vol. 97 (2) , 365-372
Role of phospholipase D2 in the agonist‐induced and constitutive endocytosis of G‐protein coupled receptors
We have recently shown that the μ‐opioid receptor [MOR1, also termed μ‐opioid peptide (MOP) receptor] is associated with the phospholipase D2 (PLD2), a phospholipid‐specific phosphodiesterase located in the plasma membrane. We further demonstrated that, in human embryonic kidney (HEK) 293 cells co‐expressing MOR1 and PLD2, treatment with (D‐Ala2, Me Phe4, Glyol5)enkephalin (DAMGO) led to an increase in PLD2 activity and an induction of receptor endocytosis, whereas morphine, which does not induce opioid receptor endocytosis, failed to activate PLD2. In contrast, a C‐terminal splice variant of the μ‐opioid receptor (MOR1D, also termed MOP1D) exhibited robust endocytosis in response to both DAMGO and morphine treatment. We report here that MOR1D also mediates an agonist‐independent (constitutive) PLD2‐activation facilitating agonist‐induced and constitutive receptor endocytosis. Inhibition of PLD2 activity by over‐expression of a dominant negative PLD2 (nPLD2) blocked the constitutive PLD2 activation and impaired the endocytosis of MOR1D receptors. Moreover, we provide evidence that the endocytotic trafficking of the δ‐opioid receptor [DOR, also termed δ‐opioid peptide (DOP) receptor] and cannabinoid receptor isoform 1 (CB1) is also mediated by a PLD2‐dependent pathway. These data indicate the generally important role for PLD2 in the regulation of agonist‐dependent and agonist‐independent G protein‐coupled receptor (GPCR) endocytosis.
- 15 March 2006
- Published by Wiley in Journal of Neurochemistry
- Vol. 97 (2) , 365-372
Open AccessRole of phospholipase D2 in the agonist‐induced and constitutive endocytosis of G‐protein coupled receptors
We have recently shown that the μ‐opioid receptor [MOR1, also termed μ‐opioid peptide (MOP) receptor] is associated with the phospholipase D2 (PLD2), a phospholipid‐specific phosphodiesterase located in the plasma membrane. We further demonstrated that, in human embryonic kidney (HEK) 293 cells co‐expressing MOR1 and PLD2, treatment with (D‐Ala2, Me Phe4, Glyol5)enkephalin (DAMGO) led to an increase in PLD2 activity and an induction of receptor endocytosis, whereas morphine, which does not induce opioid receptor endocytosis, failed to activate PLD2. In contrast, a C‐terminal splice variant of the μ‐opioid receptor (MOR1D, also termed MOP1D) exhibited robust endocytosis in response to both DAMGO and morphine treatment. We report here that MOR1D also mediates an agonist‐independent (constitutive) PLD2‐activation facilitating agonist‐induced and constitutive receptor endocytosis. Inhibition of PLD2 activity by over‐expression of a dominant negative PLD2 (nPLD2) blocked the constitutive PLD2 activation and impaired the endocytosis of MOR1D receptors. Moreover, we provide evidence that the endocytotic trafficking of the δ‐opioid receptor [DOR, also termed δ‐opioid peptide (DOP) receptor] and cannabinoid receptor isoform 1 (CB1) is also mediated by a PLD2‐dependent pathway. These data indicate the generally important role for PLD2 in the regulation of agonist‐dependent and agonist‐independent G protein‐coupled receptor (GPCR) endocytosis.
- 1 January 2005
- Published by Elsevier in Molecular Pharmacology
- Vol. 67 (1) , 280-287
Receptor Endocytosis Counteracts the Development of Opioid Tolerance
In contrast to endogenous opioids, the highly addictive drug morphine activates the μ-opioid receptor without causing its rapid endocytosis. It has recently been reported that coapplication of low concentrations of [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) facilitates the ability of morphine to stimulate μ-opioid receptor endocytosis and prevents the development of morphine tolerance in rats. To investigate the clinical relevance of this finding for analgesic therapy, the endocytotic efficacies of a series of clinically used opioids were determined, and the effect of a combination of these drugs with morphine on the μ-opioid receptor endocytosis in receptor-expressing human embryonic kidney (HEK) 293 cells was quantified. The combination of morphine and opioid drugs with high endocytotic efficacies (e.g., DAMGO, etonitazene, sufentanil, β-endorphin, piritramide, or methadone) did not result in a facilitation of morphine-mediated endocytosis but rather in a decrease of the receptor endocytosis mediated by the tested opioid drugs. These findings demonstrate a partial agonistic effect of morphine on the agonist-induced receptor endocytosis. Moreover, we demonstrated that the endocytotic potencies of opioid drugs are negatively correlated with their ability to cause receptor desensitization and opioid tolerance in HEK 293 cells. These results strongly support the hypothesis that μ-opioid receptor endocytosis counteracts receptor desensitization and opioid tolerance by inducing fast receptor reactivation and recycling. In addition, it is shown that agonist-induced receptor endocytosis facilitates the compensatory up-regulation of the cAMP pathway, a cellular hallmark of opioid withdrawal. Our findings suggest that opioids with high endocytotic efficacies might cause reduced opioid tolerance but can facilitate compensatory mechanisms, resulting in an enhanced opioid dependence.
- 1 January 2005
- Published by Elsevier in Molecular Pharmacology
- Vol. 67 (1) , 280-287
Receptor Endocytosis Counteracts the Development of Opioid Tolerance
In contrast to endogenous opioids, the highly addictive drug morphine activates the μ-opioid receptor without causing its rapid endocytosis. It has recently been reported that coapplication of low concentrations of [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) facilitates the ability of morphine to stimulate μ-opioid receptor endocytosis and prevents the development of morphine tolerance in rats. To investigate the clinical relevance of this finding for analgesic therapy, the endocytotic efficacies of a series of clinically used opioids were determined, and the effect of a combination of these drugs with morphine on the μ-opioid receptor endocytosis in receptor-expressing human embryonic kidney (HEK) 293 cells was quantified. The combination of morphine and opioid drugs with high endocytotic efficacies (e.g., DAMGO, etonitazene, sufentanil, β-endorphin, piritramide, or methadone) did not result in a facilitation of morphine-mediated endocytosis but rather in a decrease of the receptor endocytosis mediated by the tested opioid drugs. These findings demonstrate a partial agonistic effect of morphine on the agonist-induced receptor endocytosis. Moreover, we demonstrated that the endocytotic potencies of opioid drugs are negatively correlated with their ability to cause receptor desensitization and opioid tolerance in HEK 293 cells. These results strongly support the hypothesis that μ-opioid receptor endocytosis counteracts receptor desensitization and opioid tolerance by inducing fast receptor reactivation and recycling. In addition, it is shown that agonist-induced receptor endocytosis facilitates the compensatory up-regulation of the cAMP pathway, a cellular hallmark of opioid withdrawal. Our findings suggest that opioids with high endocytotic efficacies might cause reduced opioid tolerance but can facilitate compensatory mechanisms, resulting in an enhanced opioid dependence.
- Open Access
- 17 December 2003
- Published by Wiley in Journal of Neurochemistry
- Vol. 88 (3) , 680-688
Phospholipase D2 modulates agonist‐induced µ‐opioid receptor desensitization and resensitization
Receptor phosphorylation, arrestin binding, uncoupling from G protein and subsequent endocytosis have been implicated in G protein‐coupled receptor desensitization after chronic agonist exposure. In search of proteins regulating the µ‐opioid receptor endocytosis, we have recently established that activation of phospholipase D (PLD)2 is required for agonist‐induced µ‐opioid receptor endocytosis. In this study, we determined the effect of PLD2 activity on the desensitization and resensitization rate of the µ‐opioid receptor. We clearly demonstrated that inhibition of PLD2‐mediated phosphatidic acid formation by alcohol (1‐butanol or ethanol) or overexpression of a dominant negative mutant of PLD2 prevented agonist‐mediated endocytosis and resulted in a faster desensitization rate of the µ‐opioid receptor after chronic (d‐Ala2, Me Phe4, Glyol5)enkephalin treatment in human embryonic kidney 293 cells. Moreover, inhibition of PLD2 activity led to an impairment of the resensitization rate of the µ‐opioid receptor. In summary, our data strongly suggest that PLD2 is a modulator of agonist‐induced endocytosis, desensitization and resensitization of the µ‐opioid receptor.
- 17 December 2003
- Published by Wiley in Journal of Neurochemistry
- Vol. 88 (3) , 680-688
Open AccessPhospholipase D2 modulates agonist‐induced µ‐opioid receptor desensitization and resensitization
Receptor phosphorylation, arrestin binding, uncoupling from G protein and subsequent endocytosis have been implicated in G protein‐coupled receptor desensitization after chronic agonist exposure. In search of proteins regulating the µ‐opioid receptor endocytosis, we have recently established that activation of phospholipase D (PLD)2 is required for agonist‐induced µ‐opioid receptor endocytosis. In this study, we determined the effect of PLD2 activity on the desensitization and resensitization rate of the µ‐opioid receptor. We clearly demonstrated that inhibition of PLD2‐mediated phosphatidic acid formation by alcohol (1‐butanol or ethanol) or overexpression of a dominant negative mutant of PLD2 prevented agonist‐mediated endocytosis and resulted in a faster desensitization rate of the µ‐opioid receptor after chronic (d‐Ala2, Me Phe4, Glyol5)enkephalin treatment in human embryonic kidney 293 cells. Moreover, inhibition of PLD2 activity led to an impairment of the resensitization rate of the µ‐opioid receptor. In summary, our data strongly suggest that PLD2 is a modulator of agonist‐induced endocytosis, desensitization and resensitization of the µ‐opioid receptor.
- Open Access
- 1 March 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (11) , 9979-9985
ADP-ribosylation Factor-dependent Phospholipase D2 Activation Is Required for Agonist-induced μ-Opioid Receptor Endocytosis
- 1 March 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (11) , 9979-9985
Open AccessADP-ribosylation Factor-dependent Phospholipase D2 Activation Is Required for Agonist-induced μ-Opioid Receptor Endocytosis
- Open Access
- 1 August 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (33) , 31408-31414
C-terminal Splice Variants of the Mouse µ-Opioid Receptor Differ in Morphine-induced Internalization and Receptor Resensitization
- 1 August 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (33) , 31408-31414
Open AccessC-terminal Splice Variants of the Mouse µ-Opioid Receptor Differ in Morphine-induced Internalization and Receptor Resensitization